Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

The world is more than surprised that Donald Trump has scored an upset victory over rival Hillary Clinton. Many brokerage firms and economists said that a Trump victory would be awful ... Read Full Story »

Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) reported its third-quarter financial results before the markets opened on Monday. The stock saw a handy gain early on Monday even, though the company had a ... Read Full Story »

Shares of Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) saw a modest gain early Monday after the company announced a recent U.S. Food and Drug Administration (FDA) decision. Specifically, the FDA said that ... Read Full Story »

Shares of Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) were down handily on Monday. The drop follows news that JPMorgan downgraded the stock to Underweight from Neutral. The firm also set a $7 price target. ... Read Full Story »

One of the best market conditions for active traders is one in which price momentum underperforms and then kicks back in with a vengeance, and given what we have experienced since ... Read Full Story »

U.S. Food and Drug Administration (FDA) rulings and the results from clinical trials have proven time and again that they can make or break companies. The biotech and pharmaceutical companies ... Read Full Story »

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount ... Read Full Story »

The solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent ... Read Full Story »

Big pharmaceutical and biotech companies seeking to grow company sales and revenues have two solid avenues. One is a consistent and growing pipeline full with good potential drugs in clinical ... Read Full Story »

Stocks were trying to post a recovery on Thursday morning on the heels of three days worth of energy-related selling. Despite a relatively harsh drop, investors have proven over and ... Read Full Story »